These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 8083972

  • 1. Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization.
    Tanaka Y, Tanaka R, Terada E, Koyanagi Y, Miyano-Kurosaki N, Yamamoto N, Baba E, Nakamura M, Shida H.
    J Virol; 1994 Oct; 68(10):6323-31. PubMed ID: 8083972
    [Abstract] [Full Text] [Related]

  • 2. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
    Tanaka Y, Zeng L, Shiraki H, Shida H, Tozawa H.
    J Immunol; 1991 Jul 01; 147(1):354-60. PubMed ID: 1711082
    [Abstract] [Full Text] [Related]

  • 3. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
    Baba E, Nakamura M, Tanaka Y, Kuroki M, Itoyama Y, Nakano S, Niho Y.
    J Immunol; 1993 Jul 15; 151(2):1013-24. PubMed ID: 7687611
    [Abstract] [Full Text] [Related]

  • 4. Protection of rabbits against HTLV-II infection with a synthetic peptide corresponding to HTLV-II neutralization region.
    Kariya N, Hayashi K, Hoshino H, Tanaka Y, Koirala TR, Ohara N, Miyamoto K, Akagi T.
    Arch Virol; 1996 Jul 15; 141(3-4):471-80. PubMed ID: 8645089
    [Abstract] [Full Text] [Related]

  • 5. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1.
    Kuroki M, Nakamura M, Itoyama Y, Tanaka Y, Shiraki H, Baba E, Esaki T, Tatsumoto T, Nagafuchi S, Nakano S.
    J Immunol; 1992 Aug 01; 149(3):940-8. PubMed ID: 1378869
    [Abstract] [Full Text] [Related]

  • 6. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
    Palker TJ, Tanner ME, Scearce RM, Streilein RD, Clark ME, Haynes BF.
    J Immunol; 1989 Feb 01; 142(3):971-8. PubMed ID: 2563272
    [Abstract] [Full Text] [Related]

  • 7. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.
    Lairmore MD, DiGeorge AM, Conrad SF, Trevino AV, Lal RB, Kaumaya PT.
    J Virol; 1995 Oct 01; 69(10):6077-89. PubMed ID: 7545241
    [Abstract] [Full Text] [Related]

  • 8. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
    Baba E, Nakamura M, Ohkuma K, Kira J, Tanaka Y, Nakano S, Niho Y.
    J Immunol; 1995 Jan 01; 154(1):399-412. PubMed ID: 7527817
    [Abstract] [Full Text] [Related]

  • 9. Generation and characterization of monoclonal antibodies against multiple epitopes on the C-terminal half of envelope gp46 of human T-cell leukemia virus type-I (HTLV-I).
    Tanaka Y, Yasumoto M, Nyunoya H, Ogura T, Kikuchi M, Shimotohno K, Shiraki H, Kuroda N, Shida H, Tozawa H.
    Int J Cancer; 1990 Oct 15; 46(4):675-81. PubMed ID: 1698731
    [Abstract] [Full Text] [Related]

  • 10. Identification of a novel neutralization epitope on envelope gp46 antigen of human T-cell-leukemia virus-type-II (HTLV-II).
    Tanaka Y, Tanaka R, Hoshino H.
    Int J Cancer; 1994 Dec 01; 59(5):655-60. PubMed ID: 7525496
    [Abstract] [Full Text] [Related]

  • 11. Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46.
    Lairmore MD, Rudolph DL, Roberts BD, Dezzutti CS, Lal RB.
    Cancer Lett; 1992 Sep 14; 66(1):11-20. PubMed ID: 1360328
    [Abstract] [Full Text] [Related]

  • 12. Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene.
    Ibuki K, Funahashi SI, Yamamoto H, Nakamura M, Igarashi T, Miura T, Ido E, Hayami M, Shida H.
    J Gen Virol; 1997 Jan 14; 78 ( Pt 1)():147-52. PubMed ID: 9010298
    [Abstract] [Full Text] [Related]

  • 13. Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide.
    Frangione-Beebe M, Albrecht B, Dakappagari N, Rose RT, Brooks CL, Schwendeman SP, Lairmore MD, Kaumaya PT.
    Vaccine; 2000 Dec 08; 19(9-10):1068-81. PubMed ID: 11137241
    [Abstract] [Full Text] [Related]

  • 14. Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.
    Palker TJ, Riggs ER, Spragion DE, Muir AJ, Scearce RM, Randall RR, McAdams MW, McKnight A, Clapham PR, Weiss RA.
    J Virol; 1992 Oct 08; 66(10):5879-89. PubMed ID: 1326649
    [Abstract] [Full Text] [Related]

  • 15. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1.
    Jacobson S, Reuben JS, Streilein RD, Palker TJ.
    J Immunol; 1991 Feb 15; 146(4):1155-62. PubMed ID: 1704032
    [Abstract] [Full Text] [Related]

  • 16. Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46.
    Hadlock KG, Rowe J, Perkins S, Bradshaw P, Song GY, Cheng C, Yang J, Gascon R, Halmos J, Rehman SM, McGrath MS, Foung SK.
    J Virol; 1997 Aug 15; 71(8):5828-40. PubMed ID: 9223472
    [Abstract] [Full Text] [Related]

  • 17. Identification of exposed epitopes on the envelope glycoproteins of human T-cell lymphotropic virus type I (HTLV-I).
    Grange MP, Rosenberg AR, Horal P, Desgranges C.
    Int J Cancer; 1998 Mar 02; 75(5):804-13. PubMed ID: 9495252
    [Abstract] [Full Text] [Related]

  • 18. New approach for generation of neutralizing antibody against human T-cell leukaemia virus type-I (HTLV-I) using phage clones.
    Begum N, Horiuchi S, Tanaka Y, Yamamoto N, Ichiyama K, Yamamoto N.
    Vaccine; 2002 Jan 31; 20(9-10):1281-9. PubMed ID: 11818146
    [Abstract] [Full Text] [Related]

  • 19. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
    Tallet B, Astier-Gin T, Moynet D, Londos-Gagliardi D, Guillemain B.
    AIDS Res Hum Retroviruses; 2001 Mar 01; 17(4):337-48. PubMed ID: 11242520
    [Abstract] [Full Text] [Related]

  • 20. Identification and synthesis of the epitope for a human monoclonal antibody which can neutralize human T-cell leukemia/lymphotropic virus type I.
    Ralston S, Hoeprich P, Akita R.
    J Biol Chem; 1989 Oct 05; 264(28):16343-6. PubMed ID: 2476442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.